DREAMM-8 results for Blenrep (belantamab mafodotin) in multiple myeloma featured in a late-breaking presentation and ASCO’s Press Programme
Updated results from a supported collaborative study for Jemperli (dostarlimab) in locally advanced mismatch repair deficient rectal cancer
GSK plc (LSE/NYSE: GSK) today announced that findings across its oncology portfolio will be presented in 25 abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (31 May - 4 June) in Chicago, IL. The presentations support GSK’s ongoing focus and commitment to advance care in blood cancers, gynaecologic cancers and certain solid tumours through novel approaches.

DREAMM programme updates
Pivotal data will be shared from the DREAMM-8 and DREAMM-7 phase III trials showing the potential of belantamab mafodotin in combination versus standard of care in multiple myeloma at or after first relapse, including:

Results from the DREAMM-8 trial evaluating belantamab mafodotin in combination with pomalidomide and dexamethasone (PomDex) versus bortezomib combined with PomDex. This data was selected for inclusion in ASCO press programme (ASCO abstract #LBA105).
Subgroup analyses from the DREAMM-7 trial evaluating belantamab mafodotin plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex (ASCO abstract #7503).
Encore presentation (ASCO abstract #7543) of the primary results from DREAMM-7, originally featured in the ASCO Plenary Series on 6 February 2024.
Collaborations to improve patient care
Encouraging new data will be presented from GSK’s portfolio of supported collaborative studies and alliances that could transform outcomes for patients with cancer:

Updated results for dostarlimab in locally advanced mismatch repair deficient (dMMR) rectal cancer will be presented in a late-breaking rapid oral presentation (ASCO abstract #LBA3512), a supported collaborative study with Memorial Sloan Kettering Cancer Center. This follows data presented at the 2022 ASCO and 2023 Japanese Society of Medical Oncology Annual Meetings.
Hansoh Pharma will deliver an oral presentation on their phase II study of HS-20093 in Chinese patients with relapsed or refractory osteosarcoma (ASCO abstract #11507). Earlier this year, GSK obtained exclusive worldwide rights (excluding China’s mainland, Hong Kong, Macau and Taiwan) to progress clinical development and commercialisation of HS-20093.
Updated results will be presented from a phase 0/II trial of niraparib in patients with newly diagnosed MGMT-unmethylated glioblastoma (ASCO abstract #2002), a supported collaborative study sponsored by the Ivy Brain Tumor Center. Treatment with niraparib achieved a median overall survival of 20.3 months, compared to a historical control of 12.7 months.1,2. The safety profile was consistent with what has been previously reported in this study. Based on these results, a phase III clinical trial of niraparib versus standard of care has been accelerated, supported by GSK.
Full list of GSK’s presentations at ASCO:

see & read more on
https://www.gsk.com/en-gb/media/press-releases/new-data-at-asco-showcases-the-transformational-potential-of-gsks-oncology-portfolio/